Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 3.9% – Time to Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)’s stock price traded down 3.9% on Thursday . The stock traded as low as $37.51 and last traded at $37.51. 81,594 shares traded hands during trading, a decline of 89% from the average session volume of 719,378 shares. The stock had previously closed at $39.02.

Analyst Ratings Changes

AGIO has been the topic of a number of research reports. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Raymond James reissued an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Trading Down 5.9 %

The stock has a market capitalization of $2.09 billion, a P/E ratio of 3.23 and a beta of 0.80. The firm’s fifty day moving average is $50.06 and its 200-day moving average is $46.78.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Erste Asset Management GmbH acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at $97,199,000. Marshall Wace LLP raised its holdings in Agios Pharmaceuticals by 307.8% during the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after purchasing an additional 855,739 shares during the last quarter. Vestal Point Capital LP bought a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $33,767,000. Frazier Life Sciences Management L.P. lifted its position in Agios Pharmaceuticals by 66.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after purchasing an additional 348,808 shares during the period. Finally, Candriam S.C.A. bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $13,922,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.